In our updated systematic review that now includes over 40 additional RCTs and over 2000 additional patients, aside from fever, we continue to detect no significant reported safety signals associated with MSC treatment.
On the basis of the positive results of preclinical studies, the use of MSC in around of 1,000 clinical trials over 10,000 patients in multiple indications as diverse as musculoskeletal defects; disorders of the immune system including auto-immune diseases, bone, heart, liver, lung, and kidney; or neurodegenerative disorders. Besides this, it has been reported that MSC therapy does not have any unfavorable side effects on the patient. Safety of MSC therapy has been reported in a systematic review of several clinical trials involving over 1,000 participants with intravascular MSC transplantation for different diseases, with follow-up of about 2 weeks to 30 months.
